期刊文献+

急诊PCI前应用替罗非班联合治疗老年急性ST段抬高性心肌梗死患者的临床疗效 被引量:1

下载PDF
导出
摘要 目的:探讨老年患者发生急性ST段抬高心肌梗死(acute myocardial infarction with ST segment elevation,STEMI)后,在急诊经皮冠状动脉介入治疗(percutaneuos coronary intervention,PCI)前应用国产替罗非班的有效性和安全性。方法:入选连续收治并成功行急诊PCI的98例老年STEMI患者,随机分为术前应用替罗非班组46例,对照组(未应用替罗非班)52例,比较两组用药后24h、30天及术后6个月心血管事件及出血并发症。结果:术后替罗非班组与穿刺有关并发症9例,对照组7例,替罗非班组多于对照组,但二者差异无统计学意义(P=0.415);术后1个月及6个月两组EF无差异(P>0.05);术后1个月替罗非班组心血管事件3例,对照组11例(P=0.039),术后6个月替罗非班组心血管事件4例,对照组13例(P=0.046)。结论:急诊PCI前应用国产替罗非班治疗老年STEMI的患者安全有效,能降低术后1个月及6个月内心血管事件,不增加出血事件。
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2010年第10期1432-1434,1438,共4页 Journal of Nanjing Medical University(Natural Sciences)
  • 相关文献

参考文献10

  • 1杨跃进,尤士杰.急性心肌梗死恢复期应当在最佳时期开通闭塞的梗死相关动脉[J].心血管病学进展,2007,28(2):186-188. 被引量:10
  • 2李瑞建,陈玉国,张运,孙祎,徐峰,吕瑞娟,纪求尚,李继福,李贵双.早期应用替罗非班对急诊冠脉介入术后心肌微循环再灌注的影响[J].中国新药与临床杂志,2007,26(3):207-211. 被引量:17
  • 3彭志松,叶飞,陈绍良,朱中生,张俊杰,林松.血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗老年ACS的研究[J].实用老年医学,2006,20(5):331-332. 被引量:16
  • 4Zahn R,Schiele R,Schneider S,et al.Primary angioplasty VS intravenous thrombolysis in acute myocardial infarction:can we define subgroups of patients benefiring most from primary angioplasty?Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction and M. Journal of the American College of Cardiology . 2001
  • 5Rezkalla SH,Kloner RA.No-reflow phenomenon. Circulation . 2002
  • 6Elezi S,Kastrati A,Pache J,et al.Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. Journal of the American College of Cardiology . 1998
  • 7Ong AT,Hoye A,Aoki J,et al.Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. Journal of the American College of Cardiology . 2005
  • 8Maillard L,Hamon M,Khalife K,et al.A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology . 2000
  • 9Knobler H,Savion N,Shenkman B,et al.Shear-inducedplatelet adhesion and aggregation on subendothelium are in-creased in diabeticients. Thrombosis Research . 1998
  • 10Alexander KP,Chen AY,Newby LK,et al.Sex differences in major bleeding with glycoproteinⅡb/Ⅲa inhibitors:results from the CRUSADE (Can Rapid risk stratification of unstable angina patients suppress adverse outcome with early implementation of the ACC/AHA guidelines) initiative. Circulation . 2006

二级参考文献23

  • 1赵京林,杨跃进,吴永建,荆志成,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润林,陈在嘉.抗血小板药物对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(31):2187-2191. 被引量:20
  • 2陈玉国,孙祎,张运,徐峰,吕瑞娟,李瑞建.氯吡格雷对非ST抬高急性冠脉综合征病人炎症因子及其预后的影响[J].中国新药与临床杂志,2006,25(6):413-416. 被引量:13
  • 3Lincoff AM,Popma JJ,Ellis SG,et al.Abrupt vessel closure complicating coronary angioplasty:clinical,angiographic and therapeutic profile[J].J Am Coll Cardiol,1992,19(5):936.
  • 4The EPIC investigators.Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956.
  • 5Sekiguchi M,Hoshizaki H,Adachi H,et al.Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting:A randomized comparison of ticlopidine and cilostazol[J].Circ J,2004,68(7):610.
  • 6Elliott MA,Marc C,Peter JLMB,et al.The TIMI risk score for unstable angina/non-ST elevation MI:A method for prognostication and therapeutic decision making[J].JAMA,2000,284(8):835.
  • 7The platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) trial investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[J].N Engl J Med,1998,338(3):1488.
  • 8The platelet receptor inhibition for ischemic syndrome management (PRISM) study investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina[J].N Engl J Med,1998,338(3):1498.
  • 9de Feyter PJ,van den Brand M,Laarman GJ,et al.Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty[J].Circulation,1991,83(3):927.
  • 10FERGUSON JJ,LAU TK.New antiplatelet agents for acute coronary syndromes[J].Am Heart J,1998,135(5 Pt 2 Su):S194-S200.

共引文献31

同被引文献30

  • 1顾俊,马康华.血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性冠状动脉综合征中的应用[J].心血管病学进展,2009,30(6):949-953. 被引量:1
  • 2范卫泽,傅向华,姜云发,谷新顺,吴伟力,李世强,刘君,郝国桢,薛玲,李亮.冠脉内联合应用山莨菪碱和替罗非班对急性心肌梗死PCI后无再流的逆转作用[J].中国老年学杂志,2007,27(8):762-764. 被引量:6
  • 3Ercan E, Bozdemir H, Tengiz I, et al. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris [ J ]. Thromb J, 2004, 2(1):4.
  • 4Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-al- pha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS lb study[J]. J Am Coll Cardiol, 2006, 48(11): 2 186-191.
  • 5Huber K, Holmes DR JR, Vant Hof AW, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial [J]. Eur Heart J, 2010, 31(14): 1 708-716.
  • 6Rakowski T, Siudak Z, Dziewierz A, et al. Early abcix- imab administration before transfer for primary percutane- ous coronary interventions for ST-elevation myocardial in- farction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry[ J]. Am Heart J, 2009, 158(4) : 569-575.
  • 7Galasso G, Piscione F, Furbatto F, et al. Abciximab inelderly with acute coronary syndrome invasively treated: effect on outcome [ J ]. Int J Cardiol, 2008, 130 ( 3 ) : 380-385.
  • 8Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clini- cal outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre- treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial[ J ]. Eur Heart J, 2008, 29 (4) : 455- 461.
  • 9Iijima R, Ndrepepa G, Mehilli J, et al. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes [J]. Am J Cardiol, 2008, 101(9) : 1 2262231.
  • 10Auditorium L. Earlier administration of high-dose bolus tirofiban in STEMI increases benefit without increasing bleeding complications [ J ]. Cardiovasc J Afr, 2009, 20 (4) : 268.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部